Tirdzniecība DiaMedica Therapeutics Inc. - DMAC CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 0.0684 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
Nakts laika nodeva | 22:00 (UTC) | ||||||||
Min. tirgotais daudzums | 1 | ||||||||
Valūta | USD | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | United States of America | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Iepriekš. aizvērt* | 1.3501 |
Atvērt* | 1.3007 |
Izmaiņas par 1 gadu* | -49.59% |
Dienas Diapazons* | 1.2608 - 1.3306 |
52 ned Diapazons | 1.12-3.23 |
Vidējais apjoms (10 dienas) | 31.10K |
Vidējais apjoms (3 mēneši) | 1.33M |
Tirgus Kapitalizācija | 35.96M |
Cenas/Peļņas Attiecība | -100.00K |
Izvietotās Akcijas | 26.44M |
Ieņēmumi | N/A |
EPS | -0.50 |
Dividende (Ienesīgums %) | N/A |
Beta | 1.76 |
Nākamās Peļņas Datums | Mar 13, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 1.3208 | 0.0201 | 1.55% | 1.3007 | 1.3402 | 1.2608 |
Feb 2, 2023 | 1.3501 | 0.0497 | 3.82% | 1.3004 | 1.3501 | 1.2619 |
Feb 1, 2023 | 1.3205 | -0.0096 | -0.72% | 1.3301 | 1.3502 | 1.2905 |
Jan 31, 2023 | 1.3205 | -0.0479 | -3.50% | 1.3684 | 1.3886 | 1.3198 |
Jan 30, 2023 | 1.3696 | -0.0680 | -4.73% | 1.4376 | 1.4378 | 1.3691 |
Jan 27, 2023 | 1.4285 | 0.0597 | 4.36% | 1.3688 | 1.4382 | 1.3688 |
Jan 26, 2023 | 1.4086 | -0.0188 | -1.32% | 1.4274 | 1.4871 | 1.3691 |
Jan 25, 2023 | 1.4871 | 0.0400 | 2.76% | 1.4471 | 1.4969 | 1.4274 |
Jan 24, 2023 | 1.4868 | 0.0001 | 0.01% | 1.4867 | 1.5163 | 1.4867 |
Jan 23, 2023 | 1.5163 | 0.0888 | 6.22% | 1.4275 | 1.5166 | 1.4273 |
Jan 20, 2023 | 1.5165 | 0.0602 | 4.13% | 1.4563 | 1.5360 | 1.4272 |
Jan 19, 2023 | 1.5066 | 0.0793 | 5.56% | 1.4273 | 1.5361 | 1.4273 |
Jan 18, 2023 | 1.5357 | 0.0103 | 0.68% | 1.5254 | 1.5946 | 1.4565 |
Jan 17, 2023 | 1.5851 | 0.0101 | 0.64% | 1.5750 | 1.6046 | 1.5453 |
Jan 13, 2023 | 1.5850 | 0.0297 | 1.91% | 1.5553 | 1.5948 | 1.5552 |
Jan 12, 2023 | 1.5654 | 0.0494 | 3.26% | 1.5160 | 1.5655 | 1.5160 |
Jan 11, 2023 | 1.5459 | -0.0195 | -1.25% | 1.5654 | 1.5753 | 1.4961 |
Jan 10, 2023 | 1.5555 | 0.0297 | 1.95% | 1.5258 | 1.5753 | 1.4373 |
Jan 9, 2023 | 1.5753 | 0.1179 | 8.09% | 1.4574 | 1.5753 | 1.3986 |
Jan 6, 2023 | 1.4089 | 0.0398 | 2.91% | 1.3691 | 1.4089 | 1.3691 |
DiaMedica Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kopējie ienākumi | 0 | 0 | 0.5 | 0 | 0 | 0 |
Kopējie Darbības Izdevumi | 2.48146 | 4.519 | 7.261 | 11.593 | 12.699 | 13.646 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 0.71805 | 1.313 | 2.739 | 3.693 | 4.389 | 4.881 |
Pētniecība un Attīstība | 1.7612 | 3.206 | 4.522 | 7.9 | 8.31 | 8.765 |
Depreciation / Amortization | 0.00221 | |||||
Darbības Izdevumi | -2.48146 | -4.519 | -6.761 | -11.593 | -12.699 | -13.646 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.06302 | 0.009 | -0.039 | 0 | ||
Citi, Neto | 0.21761 | 0.25 | 1.146 | 0.975 | 0.434 | 0.082 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -2.20083 | -4.26 | -5.654 | -10.618 | -12.265 | -13.564 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Neto Ienākumi | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Atšķaidītie Neto Ienākumi | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Atšķaidītie Ienākumi par Akcijām | 4.73575 | 5.93579 | 7.74352 | 11.9877 | 15.6803 | 20.7734 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.46944 | -0.71768 | -0.74049 | -0.88833 | -0.78391 | -0.6543 |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.46944 | -0.71768 | -0.74049 | -0.88833 | -0.78391 | -0.6543 |
Ienākumi | 0 | 0.5 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
Kopējie Darbības Izdevumi | 3.619 | 3.365 | 3.416 | 3.246 | 3.536 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 1.213 | 1.209 | 1.084 | 1.375 | 1.562 |
Pētniecība un Attīstība | 2.406 | 2.156 | 2.332 | 1.871 | 1.974 |
Darbības Izdevumi | -3.619 | -3.365 | -3.416 | -3.246 | -3.536 |
Citi, Neto | 0.004 | 0.098 | -0.027 | 0.007 | 0.035 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -3.615 | -3.267 | -3.443 | -3.239 | -3.501 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Neto Ienākumi | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Atšķaidītie Neto Ienākumi | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Atšķaidītie Ienākumi par Akcijām | 18.7667 | 18.7862 | 19.0357 | 26.5021 | 26.4431 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.193 | -0.17428 | -0.18124 | -0.12248 | -0.13266 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.193 | -0.17428 | -0.18124 | -0.12248 | -0.13266 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 1.85356 | 1.494 | 17.972 | 8.836 | 27.921 | 45.439 |
Nauda un Īstermiņa Ieguldījumi | 1.73636 | 1.353 | 16.823 | 7.878 | 27.507 | 45.112 |
Cash | 1.73636 | 1.353 | 16.823 | 3.883 | 7.409 | 4.707 |
Debitoru Parādu Kopsumma, Neto | 0.05197 | 0.08 | 0.78 | 0.823 | 0.34 | 0.13 |
Prepaid Expenses | 0.06522 | 0.061 | 0.369 | 0.047 | 0.064 | 0.084 |
Total Assets | 1.87295 | 1.802 | 18.339 | 9.053 | 28.095 | 45.551 |
Property/Plant/Equipment, Total - Net | 0.0194 | 0.037 | 0.096 | 0.217 | 0.174 | 0.112 |
Property/Plant/Equipment, Total - Gross | 0.0422 | 0.26 | 0.231 | 0.179 | ||
Accumulated Depreciation, Total | -0.0228 | -0.043 | -0.057 | -0.067 | ||
Total Current Liabilities | 0.62697 | 1.003 | 1.296 | 1.318 | 2.028 | 1.524 |
Accounts Payable | 0.32663 | 0.182 | 1.099 | 0.509 | ||
Accrued Expenses | 0.24533 | 1.13 | 0.923 | 1.011 | ||
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.05501 | 0.084 | 0 | |||
Total Liabilities | 0.62697 | 1.003 | 1.314 | 1.436 | 2.081 | 1.527 |
Total Long Term Debt | 0 | 0 | 0.018 | 0.013 | 0.007 | 0.003 |
Other Liabilities, Total | 0 | 0.105 | 0.046 | 0 | ||
Total Equity | 1.24599 | 0.799 | 17.025 | 7.617 | 26.014 | 44.024 |
Common Stock | 40.9937 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 6.21111 | 41.033 | 62.993 | 64.232 | 94.925 | 126.576 |
Retained Earnings (Accumulated Deficit) | -46.5459 | -40.234 | -45.968 | -56.617 | -68.909 | -82.501 |
Other Equity, Total | 0.58708 | 0.002 | -0.002 | -0.051 | ||
Total Liabilities & Shareholders’ Equity | 1.87295 | 1.802 | 18.339 | 9.053 | 28.095 | 45.551 |
Total Common Shares Outstanding | 5.52605 | 6.37066 | 11.9569 | 12.0069 | 18.7462 | 26.4431 |
Accounts Receivable - Trade, Net | 0.08 | 0.78 | 0.13 | |||
Other Long Term Assets, Total | 0.271 | 0.271 | 0 | |||
Payable/Accrued | 0.919 | 1.291 | ||||
Current Port. of LT Debt/Capital Leases | 0 | 0.005 | 0.006 | 0.006 | 0.004 | |
Capital Lease Obligations | 0 | 0.018 | 0.013 | 0.007 | 0.003 | |
Īstermiņa Ieguldījumi | 3.995 | 20.098 | 40.405 | |||
Other Current Assets, Total | 0.088 | 0.01 | 0.113 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 24.195 | 21.629 | 48.537 | 45.439 | 42.111 |
Nauda un Īstermiņa Ieguldījumi | 23.401 | 21.295 | 48.097 | 45.112 | 41.047 |
Cash | 3.329 | 2.228 | 16.219 | 4.707 | 3.032 |
Īstermiņa Ieguldījumi | 20.072 | 19.067 | 31.878 | 40.405 | 38.015 |
Debitoru Parādu Kopsumma, Neto | 0.337 | 0.016 | 0.104 | 0.13 | 0.168 |
Prepaid Expenses | 0.457 | 0.318 | 0.336 | 0.084 | 0.793 |
Total Assets | 24.356 | 21.774 | 48.664 | 45.551 | 42.211 |
Property/Plant/Equipment, Total - Net | 0.161 | 0.145 | 0.127 | 0.112 | 0.1 |
Property/Plant/Equipment, Total - Gross | 0.209 | 0.199 | 0.187 | 0.179 | 0.162 |
Accumulated Depreciation, Total | -0.048 | -0.054 | -0.06 | -0.067 | -0.062 |
Total Current Liabilities | 1.178 | 1.44 | 1.624 | 1.524 | 1.434 |
Accounts Payable | 0.689 | 0.239 | 0.699 | 0.509 | 0.433 |
Accrued Expenses | 0.483 | 1.196 | 0.921 | 1.011 | 0.995 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.006 | 0.005 | 0.004 | 0.004 | 0.006 |
Total Liabilities | 1.211 | 1.456 | 1.628 | 1.527 | 1.443 |
Total Long Term Debt | 0.005 | 0.005 | 0.004 | 0.003 | 0.009 |
Capital Lease Obligations | 0.005 | 0.005 | 0.004 | 0.003 | 0.009 |
Other Liabilities, Total | 0.028 | 0.011 | 0 | 0 | |
Total Equity | 23.145 | 20.318 | 47.036 | 44.024 | 40.768 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 95.68 | 96.126 | 126.296 | 126.576 | 126.884 |
Retained Earnings (Accumulated Deficit) | -72.531 | -75.805 | -79.255 | -82.501 | -86.009 |
Other Equity, Total | -0.004 | -0.003 | -0.005 | -0.051 | -0.107 |
Total Liabilities & Shareholders’ Equity | 24.356 | 21.774 | 48.664 | 45.551 | 42.211 |
Total Common Shares Outstanding | 18.7862 | 18.7862 | 26.4392 | 26.4431 | 26.4431 |
Accounts Receivable - Trade, Net | 0.13 | 0.166 | |||
Other Current Assets, Total | 0.113 | 0.103 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Nauda no Darbības | -3.02318 | -3.9 | -5.696 | -9.102 | -9.185 | -12.252 |
Nauda no Darbības | 0.0022 | 0.004 | 0.015 | 0.021 | 0.021 | 0.024 |
Bezskaidras Naudas Preces | 0.14174 | 0.4 | 0.659 | 1.139 | 1.891 | 1.777 |
Samaksātie Procenti Naudā | 0.02552 | 0.002 | 0.002 | |||
Izmaiņas Apgrozāmajā Kapitālā | -0.94397 | -0.044 | -0.636 | 0.387 | 1.195 | -0.461 |
Nauda no Ieguldījumu Darbībām | -0.00689 | -0.022 | -0.05 | -3.908 | -16.134 | -20.537 |
Kapitālie Izdevumi | -0.00689 | -0.022 | -0.05 | -0.002 | -0.047 | -0.022 |
Nauda no Darbībām ar Finansēšanu | 4.59263 | 3.539 | 21.216 | 0.07 | 28.845 | 30.087 |
Akciju Izsniegšana (Atkāpšanās), Neto | 4.59263 | 3.539 | 21.216 | 0.075 | 28.85 | 30.093 |
Ārvalstu Valūtas Ietekme | 0.00767 | |||||
Neto Izmaiņas Naudā | 1.57023 | -0.383 | 15.47 | -12.94 | 3.526 | -2.702 |
Cash Taxes Paid | 0.026 | 0.036 | 0.028 | |||
Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -3.906 | -16.087 | -20.515 | |||
Parādu Izsniegšana (Atkāpšanās), Neto | -0.005 | -0.005 | -0.006 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.622 | -6.896 | -10.346 | -13.592 | -3.508 |
Cash From Operating Activities | -4.313 | -6.402 | -9.448 | -12.252 | -3.888 |
Cash From Operating Activities | 0.006 | 0.012 | 0.018 | 0.024 | 0.006 |
Non-Cash Items | 0.551 | 1.023 | 1.354 | 1.777 | 0.443 |
Changes in Working Capital | -1.248 | -0.541 | -0.474 | -0.461 | -0.829 |
Cash From Investing Activities | -0.009 | 0.98 | -11.848 | -20.537 | 2.214 |
Capital Expenditures | -0.009 | -0.013 | -0.015 | -0.022 | 0 |
Other Investing Cash Flow Items, Total | 0 | 0.993 | -11.833 | -20.515 | 2.214 |
Cash From Financing Activities | 0.242 | 0.241 | 30.106 | 30.087 | -0.001 |
Issuance (Retirement) of Stock, Net | 0.244 | 0.244 | 30.111 | 30.093 | 0 |
Issuance (Retirement) of Debt, Net | -0.002 | -0.003 | -0.005 | -0.006 | -0.001 |
Net Change in Cash | -4.08 | -5.181 | 8.81 | -2.702 | -1.675 |
Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
---|---|---|---|---|---|---|
EQT Partners AB | Private Equity | 10.8 | 2855847 | 304827 | 2022-07-08 | LOW |
Trill AB,LLC. | Corporation | 9.6472 | 2551020 | 2551020 | 2021-09-28 | |
Jacinto (Richard II) | Individual Investor | 9.4543 | 2500000 | 850947 | 2022-12-31 | LOW |
Lytton (Laurence W) | Individual Investor | 4.0539 | 1071970 | -308296 | 2021-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9597 | 782640 | 0 | 2022-09-30 | LOW |
Giuffre (Randall Michael) | Individual Investor | 1.4983 | 396184 | 35130 | 2023-01-03 | LOW |
Omega Advisors, Inc. | Investment Advisor | 1.1345 | 300000 | 100000 | 2021-12-31 | LOW |
Jacob Asset Management of New York, LLC | Investment Advisor | 0.9019 | 238500 | 0 | 2022-09-30 | LOW |
Pilnik (Richard D) | Individual Investor | 0.7937 | 209882 | 55555 | 2023-01-03 | LOW |
Lynch (Timothy Patrick) | Individual Investor | 0.7573 | 200259 | 0 | 2021-12-31 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7004 | 185219 | 8197 | 2022-09-30 | LOW |
Burroughs (Amy Louise) | Individual Investor | 0.2772 | 73288 | 17156 | 2023-01-03 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2617 | 69198 | -11450 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 66629 | 0 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2455 | 64930 | 2153 | 2022-09-30 | LOW |
Pauls (Dietrich John) | Individual Investor | 0.211 | 55804 | 20000 | 2022-11-16 | LOW |
Alcorn Harry W Jr | Individual Investor | 0.1663 | 43981 | 399 | 2022-03-22 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1612 | 42634 | -15381 | 2022-09-30 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.1589 | 42007 | 5207 | 2022-09-30 | MED |
Two Sigma Investments, LP | Hedge Fund | 0.1491 | 39418 | -4531 | 2022-09-30 | HIGH |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com GroupTirgotāji
Ikmēneša aktīvie klienti
Ikmēneša ieguldījumu apjoms
Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
DiaMedica Therapeutics Inc. Company profile
Par DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. ir klīniskās stadijas biofarmācijas uzņēmums. Uzņēmums koncentrējas uz neiroloģisko un nieru slimību, piemēram, akūta išēmiska insulta (AIS) un hroniskas nieru slimības (CKN), ārstēšanas līdzekļu izstrādi. Uzņēmuma vadošais produkts DM199 imitē dabā sastopamo cilvēka KLK1 olbaltumvielu darbību, lai saglabātu un atjaunotu asinsriti insulta bojātajos audos un uzlabotu vispārējo nieru darbību. KLK1 ir serīna proteāze jeb proteīns, kas galvenokārt veidojas nierēs, aizkuņģa dziedzerī un siekalu dziedzeros. DM199 terapijai ir potenciāls uzlabot asinsriti un kritisko sistēmu vispārējo funkciju, kā arī mazināt iekaisumu un oksidatīvo stresu. Uzņēmumam ir arī citi produkti, kas paredzēti IgA nefropātijai un afroamerikāņiem ar CKD.
Industry: | Bio Therapeutic Drugs |
301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com